<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma fibronectin is regarded to play an important part in a decrease of the <z:mp ids='MP_0002409'>resistance to infections</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>To specify the role of fibronectin in the pathogenesis of infectious complications in patients with <z:hpo ids='HP_0000716'>depressions</z:hpo> of hemopoiesis, the content of this opsonin was measured by ELISA in 113 patients with different patterns of hemoblastoses, <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> and with an aplastic syndrome </plain></SENT>
<SENT sid="2" pm="."><plain>In 42 patients, the concentration of opsonin was measured in the presence of the <z:e sem="disease" ids="C0038826" disease_type="Disease or Syndrome" abbrv="">superimposed infection</z:e> of varying gravity </plain></SENT>
<SENT sid="3" pm="."><plain>The fibronectin content was examined in 39 patients before, during and after completion of the <z:chebi fb="0" ids="35610">cytostatic</z:chebi> polychemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>It turned out that in patients with paraproteinemic hemoblastoses, <z:e sem="disease" ids="C0036202,C0019829" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">lymphogranulomatosis</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> lympholeukemia, <z:hpo ids='HP_0011009'>acute</z:hpo> lympho- and myelo(mono)blastic <z:hpo ids='HP_0001909'>leukemias</z:hpo>, cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023473,C0023470" disease_type="Neoplastic Process" abbrv="">myelosis</z:e> and hematosarcomas, the concentration of fibronectin remained <z:mpath ids='MPATH_458'>normal</z:mpath> in the absence of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The computation of the linear correlation ratio did not reveal any association between the opsonin level and the concentration of neoplastic elements in the peripheral blood </plain></SENT>
<SENT sid="6" pm="."><plain>Repeated measurements of the fibronectin level in patients whose underlying disease ran its course in association with marked neoplastic <z:hpo ids='HP_0001945'>fever</z:hpo> failed to detect any deficiency of the <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The lowering of the fibronectin level was recorded in patients with a grave concomitant <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of the type of <z:hpo ids='HP_0100806'>sepsis</z:hpo>, necrotic <z:hpo ids='HP_0002242'>enteropathy</z:hpo> and lobar <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The degree of opsonin deficiency correlated with the patients' disease gravity </plain></SENT>
<SENT sid="9" pm="."><plain>Prolonged reduction in the blood fibronectin level was of unfavourable prognostic importance </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="35610">Cytostatic</z:chebi> polychemotherapy, myelotoxic <z:mp ids='MP_0000334'>agranulocytosis</z:mp> as well as infectious complications of low gravity did not influence the concentration of fibronectin.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>